DISCLOSURE INDEX - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

Practical Recommendations in Immuno and Molecular Oncology (PRIMO)
February 7-10 2024

Lihue, Kaua’i, HI

DISCLOSURE INDEX

The Medical Educator Consortium, Inc. in accordance with the Joint Accreditation Criteria and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, has implemented a process where everyone who is in a position to control the content of a CME/CE activity has disclosed to us all relevant financial relationships with any ineligible company that they have had over the past 24 months. There is no minimum financial threshold; disclosure must be made regardless of whether the person views the financial relationships as relevant to the education.  The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. 

 

As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all relevant financial relationships with any ineligible companies to the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.


The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.

Speakers/Moderators – Reported Relevant Financial Disclosure(s) 

Jared D. Acoba, MD 

Grant/Research Support: GSK 

Other:  Virtual Round Table:  AstraZeneca

 

Sanjiv S. Agarwala, MD 

Has no relevant financial relationships

 

Manmeet S. Ahluwalia, MD, MBA, FASCO

Grant/Research Support: AstraZeneca, AbbVie, BMS, Bayer, Incyte, Pharmacyclics, Novocure Inc., Merck, MimiVac, Seagen and Novartis

Consultant: Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Autem Therapeutics

Stock Shareholders: CytoDyn, Doctible, MimiVax, and MedInnovate Advisors LLC

Scientific Advisory Board: Cairn Therapeutics, Pyramid Biosciences, Modifi Biosciences., Bugworks



Daniel H. Ahn, DO, MS

Grant/Research Support: Bayer, AstraZeneca

Consultant: Incyte, Exelixis, Novartis

Stock Shareholders: Natera 

 

Paul A. Bunn, MD 

Consultant/DMC: BMS, Daiichi, Merck

Consultant: C Stone Pharmaceuticals, Ascentage, Imidex, AstraZeneca,Genentech, Verastem

 

Michael Carney, MD

Has no relevant financial relationships

 

Don S. Dizon, MD, FACP, FASCO

Grant/Research Support: Bristol Myers Squibb

Consultant: AstraZeneca, Glaxo SmithKline, Pfizer

Stock Shareholders: Midi, Doximity

 

Benjamin Falit, MD, JD

Has no relevant financial relationships

 

Jami Fukui, MD

Grant/Research Support: Hope Foundation (Ended)

 

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Grant/Research Support: Pharmacosmos 

 

Barbara Goff, MD

Has no relevant financial relationships

 

William J. Gradishar MD, FASCO, FACP

Consultant: Roche/Genentech, AstraZeneca, SeaGen, Immunomedics, Novartis, Gilead, Lilly

 

Matthew Gubens, MD, MS

Grant/Research Support: Amgen, JNJ, Merck, OncoMed, Trizell

Consultant: AnHeart, AstraZeneca, Atreca, Cardinal Health, Genzyme, Genentech/Roche, Gilead, Guardant, Invitae, iTeos, Merus, Sanofi, Summit, Surface Oncology

 

Scott Huntington, MD, MPH

Grant/Research Support: Celgene, DTRM BioPharma, TG Therapeutics, Debiopharm Group, Agios

Consultant: SeaGen, Janssen, Bayer, BeiGene, Epizyme, Lilly, Servier, Genentech, Abbvie, Flatiron, Novartis, BeiGene, AstraZeneca, ADC Therapeutics, Merck, TG Therapeutics, TYME Technologies Inc., Arvinas, Pharmacyclics, AstraZeneca

 

Komal Jhaveri, MD, FACP

Grant/Research Support: Novartis, Genentech, Astra Zeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer, Lilly Pharmaceuticals, Zymeworks, Gilead, PUMA Biotechnology, Merck Pharmaceuticals, Scorpion Therapeutics, Blueprint Medicine

Consultant: Novartis, Pfizer, BMS, Jounce Therapeutics, Taiho Oncology, Genentech/Roche, AbbVie, Eisai, Astra Zeneca, Blueprint Medicine, Daiichi Sankyo, Seattle Genetics, Lilly/Loxo Oncology, Sun Pharma Advanced Research Company Ltd, Menarini/Stemline, Scorpion 

Therapeutics

 

Catherine Lai, MD, MPH

Consultant: Jazz Pharma, PDS Biotechnology, Astellas (All Ended)

Speakers’ Bureau: OncLive, BioAscent (All Ended)

Other: Advisory: Bristol Myers Squibb, Genentech, AbbVie, Novartis, Pfizer

 

Glenn J. Lesser, MD, FACP

Grant/Research Support: Novocure Biopharma, LLC, Pharma America, ABM Therapeutics 

Consultant: Servier Pharmaceuticals, ONO Pharma, Inc

 

Sagar Lonial, MD, FACP 

Grant/Research Support: Takeda, Novartis, Janssen, BMS 

Consultant: Amgen, Novartis, BMS, GSK, ABBVIE, Genentech, Pfizer, Janssen, Takeda, Regeneron

Other: Stock TG therapeutics

 

Ravi A. Madan, MD

Has no relevant financial relationships

 

Tricia Maeda, RN, BSN

Has no relevant financial relationships

 

Shane Y. Morita, MD, MS, PhD, FACS
Has no relevant financial relationships

 

Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS
Grant/Research Support: Corcept Therapeutics, AstraZeneca

Consultant: AstraZeneca, Merck, Daiichi Sankyo, GSK, Genentech

 

Luis E. Raez, MD, FACP, FCCP

Grant/Research Support: BMS, AstraZeneca, Lilly Oncology, Merck, Pfizer Nanthealth, Natera, Guardant Health, VELOS, TG Therapeutics, LOXO Pharmaceuticals, BioAlta, Merus, Seagen

 

Hope S. Rugo, MD, FASCO 

Grant/Research Support: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics, OBI Pharma; Ambryx

Consultant/Advisory: Daiichi Sankyo; Mylan/Viatris; NAPO; Eisai

 

Ritu Salani, MD, MBA

Consultant: Merck, GSK, Seagen, Regeneron, Eisai, Up To Date, 

 

Edgardo S. Santos Castillero, MD, FACP

Consultant: AstraZeneca, Abbvie, Genentech, Sanofi, Regeneron, Novartis

Speakers’ Bureau: Amgen, AstraZeneca, Bristol-Myers Squib, Genentech, Lilly, EMD Serono, G1 Therapeutics, Jazz Pharmaceuticals, Merck, Mirati, Pfizer, Regeneron, Sanofi, Sobi Pharmaceutical Co., Takeda

 

Priyanka Sharma, MD

Grant/Research Support: Novartis, Bristol-Meyers Squibb, Merck, Gilead

Consultant/Advisory Board: Pfizer, Merck, Gilead, Seattle Genetics, Novartis, AstraZeneca, GSK

 

Rachna Shroff, MD, MS, FASCO

Grant/Research Support: Bayer, BMS, Bristol-Myers Squibb, Merck, Exelixis Pharmaceuticals, Haloyzme, Pieris, Taiho, Rafael Pharmaceuticals, IMV inc., LOXO, Novocure, NUCANA, QED Therapeutics, Seagen

Consultant/Advisory Boards: Merck, Exelixis, Seattle Genetics, QED, Debiopharm, Agios, Clovis, Astra Zeneca, Incyte, Zymeworks Biopharm., SYROS, Astellas, Natera, Hookipa Pharm., AbbVie, Duo Oncology, Ability Pharm., Servier

 

Guru P. Sonpavde, MD

Grant/Research Support: Sanofi, Astrazeneca, Gilead, Helsinn, Lucence, EMD Serono, Jazz Therapeutics

Consultant: EMD Serono, BMS, Merck, Seattle Genetics/Astellas, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Lucence Health, IMV, Vial, Tempus, Ellipses Pharma, PrecisCa, Suba Therapeutics, Syapse, Merck, Servier, Syncorp

Speakers’ Bureau: Seagen, Gilead, Natera, Exelixis, Janssen, Bayer, Aveo

Other:  DSM:  Mereo, 

 

Ulka Vaishampayan, MD

Grant/Research Support: Merck Inc, Bristol Myers Squibb Inc

Consultant: Merck, Exelixis, Gilead, Sanofi, Alkermes, Bristol-Myers-Squibb, Bayer, Pfizer

Speakers’ Bureau: Bayer, Exelixis

 

Julie M. Vose, MD, MBA

Grant/Research Support: Abbvie, Janssen, AstraZeneca, MEI Pharma, Johnson & Johnson, Daiichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly

Consultant: Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Johnson & Johnson, Daiichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly

 

Kevin Wilcox, MD
Has no relevant financial relationships

 

Planning Committee – Reported Relevant Financial Disclosure(s) 

Sanjiv S. Agarwala, MD 

Has no relevant financial relationships


Don S. Dizon, MD, FACP, FASCO

Grant/Research Support:

Bristol Myers Squibb

Consultant: AstraZeneca, Glaxo SmithKline, Pfizer

Stock Shareholders: Midi, Doximity


Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Grant/Research Support: Pharmacosmos 


Tricia Maeda, RN, BSN

Has no relevant financial relationships


Shane Y. Morita, MD, MS, PhD, FACS
Has no relevant financial relationships


Luis E. Raez, MD, FACP, FCCP

Grant/Research Support: BMS, AstraZeneca, Lilly Oncology, Merck, Pfizer Nanthealth, Natera, Guardant Health, VELOS, TG Therapeutics, LOXO Pharmaceuticals, BioAlta, Merus, Seagen

 

Hope S. Rugo, MD, FASCO 

Grant/Research Support: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics, OBI Pharma; Ambryx

Consultant/Advisory: Daiichi Sankyo; Mylan/Viatris; NAPO; Eisai


Edgardo S. Santos Castillero, MD, FACP

Consultant: AstraZeneca, Abbvie, Genentech, Sanofi, Regeneron, Novartis

Speakers’ Bureau: Amgen, AstraZeneca, Bristol-Myers Squib, Genentech, Lilly, EMD Serono, G1 Therapeutics, Jazz Pharmaceuticals, Merck, Mirati, Pfizer, Regeneron, Sanofi, Sobi Pharmaceutical Co., Takeda


Amy Schippers, PA-C

Has no relevant financial relationships


Rachna Shroff, MD, MS, FASCO

Grant/Research Support: Bayer, BMS, Bristol-Myers Squibb, Merck, Exelixis Pharmaceuticals, Haloyzme, Pieris, Taiho, Rafael Pharmaceuticals, IMV inc., LOXO, Novocure, NUCANA, QED Therapeutics, Seagen

Consultant/Advisory Boards: Merck, Exelixis, Seattle Genetics, QED, Debiopharm, Agios, Clovis, Astra Zeneca, Incyte, Zymeworks Biopharm., SYROS, Astellas, Natera, Hookipa Pharm., AbbVie, Duo Oncology, Ability Pharm., Servier


Teri Valls, CMP, CMM

Has no relevant financial relationships


Julie M. Vose, MD, MBA

Grant/Research Support: Abbvie, Janssen, AstraZeneca, MEI Pharma, Johnson & Johnson, Daiichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly

Consultant: Abbvie, Janssen, Astra-Zeneca, MEI Pharma, Johnson & Johnson, Daiichi Sankyo, Pharmacyclics, Genentech, BMS, Lilly


CME Reviewers – Reported Relevant Financial Disclosure(s) 

Sanjiv S. Agarwala, MD 

Has no relevant financial relationships


Lynne Davidson 

Has no relevant financial relationships


Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Grant/Research Support: Pharmacosmos 


Tricia Maeda, RN, BSN

Has no relevant financial relationships


Amy Schippers, PA-C

Has no relevant financial relationships


Teri Valls, CMP, CMM

Has no relevant financial relationships


All of the relevant financial relationships listed for these individuals have been mitigated.


SPEAKERS WILL DIRECTLY DISCLOSE THE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. EACH SPEAKER HAS BEEN REQUESTED TO KEEP THEIR PRESENTATION UNBIASED AND GENERIC WHEN APPLICABLE.